Back to News
Market Impact: 0.3
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
Source: benzinga.com
Healthcare & BiotechCompany FundamentalsInvestor Sentiment & Positioning
Sarepta Therapeutics shares traded lower Tuesday following Novartis's release of global Phase 3 HARBOR study data for del-desiran in myotonic dystrophy type 1. The reaction signals investor concern that Novartis's clinical progress could strengthen competitive pressure in the DM1 treatment market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
NVS0.45
SRPT-0.35
More News
- Attacks Halt Saudi Energy Sites, Novartis Drops Most in 6 Years | The Opening Trade 9/8/2026
- Pharma major plummets over 10% after third trial disappointment in a week
- Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
- Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback
- Lilly perseveres in a bad day for drug stocks — plus, Boeing's mixed deliveries
- 'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat